Tagrisso (osimertinib) has been approved in Europe to treat Epidermal Growth Factor Receptor (EGFR) mutated non-small cell lung cancer (NSCLC) as a first-line treatment.

This offers a new line of attack at this stage of the disease (mutated lung cancer) and results from the trial show unprecedented survival benefit without progression of the disease in patients.

Find out more about the study, as well as the reach and impact of the medicine in this Pharmatimes Article.